Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...
GlobalData on MSN
Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics will still submit tovecimig for approval despite the OS miss.
Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares fell 23% to $3.85 in premarket ...
Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...
The Consumer Policy Center estimated that Compass’ market share was up to 40 percent after its deal for Anywhere Real Estate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results